326 related articles for article (PubMed ID: 26002154)
1. Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.
Hallé M; Tribout-Jover P; Lanteigne AM; Boulais J; St-Jean JR; Jodoin R; Girouard MP; Constantin F; Migneault A; Renaud F; Didierlaurent AM; Mallett CP; Burkhart D; Pilorget A; Palmantier R; Larocque D
J Immunol Methods; 2015 Sep; 424():64-79. PubMed ID: 26002154
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of glatiramer acetate and grafted CD115⁺ monocytes in a mouse model of Alzheimer's disease.
Koronyo Y; Salumbides BC; Sheyn J; Pelissier L; Li S; Ljubimov V; Moyseyev M; Daley D; Fuchs DT; Pham M; Black KL; Rentsendorj A; Koronyo-Hamaoui M
Brain; 2015 Aug; 138(Pt 8):2399-422. PubMed ID: 26049087
[TBL] [Abstract][Full Text] [Related]
3. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
5. Decreased expression of cathepsin D in monocytes is related to the defective degradation of amyloid-β in Alzheimer's disease.
Tian L; Zhang K; Tian ZY; Wang T; Shang DS; Li B; Liu DX; Fang WG; Wang ZY; Chen YH
J Alzheimers Dis; 2014; 42(2):511-20. PubMed ID: 24898658
[TBL] [Abstract][Full Text] [Related]
6. A novel role for osteopontin in macrophage-mediated amyloid-β clearance in Alzheimer's models.
Rentsendorj A; Sheyn J; Fuchs DT; Daley D; Salumbides BC; Schubloom HE; Hart NJ; Li S; Hayden EY; Teplow DB; Black KL; Koronyo Y; Koronyo-Hamaoui M
Brain Behav Immun; 2018 Jan; 67():163-180. PubMed ID: 28860067
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
[TBL] [Abstract][Full Text] [Related]
8. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.
Bohrmann B; Baumann K; Benz J; Gerber F; Huber W; Knoflach F; Messer J; Oroszlan K; Rauchenberger R; Richter WF; Rothe C; Urban M; Bardroff M; Winter M; Nordstedt C; Loetscher H
J Alzheimers Dis; 2012; 28(1):49-69. PubMed ID: 21955818
[TBL] [Abstract][Full Text] [Related]
9. Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes.
Möhle L; Israel N; Paarmann K; Krohn M; Pietkiewicz S; Müller A; Lavrik IN; Buguliskis JS; Schott BH; Schlüter D; Gundelfinger ED; Montag D; Seifert U; Pahnke J; Dunay IR
Acta Neuropathol Commun; 2016 Mar; 4():25. PubMed ID: 26984535
[TBL] [Abstract][Full Text] [Related]
10. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
[TBL] [Abstract][Full Text] [Related]
11. Active immunization of mice with an Abeta-Hsp70 vaccine.
Koller MF; Mohajeri MH; Huber M; Wollmer MA; Roth Z'graggen BV; Sandmeier E; Moritz E; Tracy J; Nitsch RM; Christen P
Neurodegener Dis; 2004; 1(1):20-8. PubMed ID: 16908970
[TBL] [Abstract][Full Text] [Related]
12. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.
Levites Y; Smithson LA; Price RW; Dakin RS; Yuan B; Sierks MR; Kim J; McGowan E; Reed DK; Rosenberry TL; Das P; Golde TE
FASEB J; 2006 Dec; 20(14):2576-8. PubMed ID: 17068112
[TBL] [Abstract][Full Text] [Related]
13. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system.
Vollmar P; Kullmann JS; Thilo B; Claussen MC; Rothhammer V; Jacobi H; Sellner J; Nessler S; Korn T; Hemmer B
J Immunol; 2010 Nov; 185(10):6338-47. PubMed ID: 20943998
[TBL] [Abstract][Full Text] [Related]
14. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
Chauhan NB; Siegel GJ
Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.
Lemere CA; Maier M; Jiang L; Peng Y; Seabrook TJ
Rejuvenation Res; 2006; 9(1):77-84. PubMed ID: 16608400
[TBL] [Abstract][Full Text] [Related]
16. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration.
Takata K; Hirata-Fukae C; Becker AG; Chishiro S; Gray AJ; Nishitomi K; Franz AH; Sakaguchi G; Kato A; Mattson MP; Laferla FM; Aisen PS; Kitamura Y; Matsuoka Y
Eur J Neurosci; 2007 Nov; 26(9):2458-68. PubMed ID: 17970733
[TBL] [Abstract][Full Text] [Related]
17. Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.
Zuroff L; Daley D; Black KL; Koronyo-Hamaoui M
Cell Mol Life Sci; 2017 Jun; 74(12):2167-2201. PubMed ID: 28197669
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for Alzheimer's disease.
Steinitz M
Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
Geylis V; Steinitz M
Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
[TBL] [Abstract][Full Text] [Related]
20. Monocytes release cystatin F dimer to associate with Aβ and aggravate amyloid pathology and cognitive deficits in Alzheimer's disease.
Li Q; Li B; Liu L; Wang KJ; Liu MY; Deng Y; Li Z; Zhao WD; Wu LY; Chen YH; Zhang K
J Neuroinflammation; 2024 May; 21(1):125. PubMed ID: 38730470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
